POLICY NUMBER UM ONC_1281	**SUBJECT** Empliciti™ (elotuzumab)		**DEPT/PROGRAM** UM Dept	**PAGE 1 OF 3**
DATES COMMITTEE REVIEWED 03/23/16, 01/05/17, 01/10/18, 01/09/19, 12/11/19, 01/08/20	**APPROVAL DATE** January 8, 2020	**EFFECTIVE DATE** January 8, 2020	**COMMITTEE APPROVAL DATES** (latest version listed last) 03/23/16, 01/05/17, 01/10/18, 01/09/19, 12/11/19, 01/08/20	
PRIMARY BUSINESS OWNER: UM **APPROVED BY:** Dr. Andrew Hertler		**COMMITTEE/BOARD APPROVAL** Utilization Management Committee		
URAC STANDARDS HUM 1		**NCQA STANDARDS** UM 2	**ADDITIONAL AREAS OF IMPACT**	
CMS REQUIREMENTS	**STATE/FEDERAL REQUIREMENTS**		**APPLICABLE LINES OF BUSINESS** All	

I. PURPOSE

To define and describe the accepted indications for Empliciti (elotuzumab) usage in the treatment of cancer.

II. DEFINITIONS

Empliciti (elotuzumab): Elotuzumab is a humanized IgG1 monoclonal antibody that specifically targets the SLAMF7 (Signaling Lymphocytic Activation Molecule Family member 7) protein. SLAMF7 is expressed on myeloma cells independent of cytogenetic abnormalities. SLAMF7 is also expressed on Natural Killer cells, plasma cells, and at lower levels on specific immune cell subsets of differentiated cells within the hematopoietic lineage.

Elotuzumab directly activates Natural Killer cells through both the SLAMF7 pathway and Fc receptors. Elotuzumab also targets SLAMF7 on myeloma cells and facilitates the interaction with Natural Killer cells to mediate the killing of myeloma cells through antibody-dependent cellular cytotoxicity (ADCC). In preclinical models, the combination of elotuzumab and lenalidomide resulted in enhanced activation of Natural Killer cells that was greater than the effects of either agent alone and increased anti-tumor activity in vitro and in vivo.

Empliciti (elotuzumab) is FDA approved in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies and in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.

Empliciti (elotuzumab) is available in 300 mg and 400 mg single-dose vials as lyophilized powder.

III. POLICY

New Century is responsible for processing all medication requests from network ordering providers. Medications not authorized by New Century may be deemed as not approvable and therefore not reimbursable. Treatment request outside the approved FDA manufacturer labeling or CMS approved compendia must be supported by, at minimum, two peer reviewed citations. If references are not produced, delays may occur to the processing of such request.

Inclusion Criteria: Empliciti (elotuzumab) may be considered medically necessary when any of the following selection criteria is met:

1. **Multiple Myeloma**
    a. Empliciti (elotuzumab) is used in combination with lenalidomide/bortezomib and dexamethasone.

i. Members with prior treatment with Lenalidomide/bortezomib will be permitted if:

1. Best response achieved was ≥Partial Response (PR) **AND**

ii. Member was not refractory **AND**

iii. Member did not discontinue due to a Grade ≥3 related adverse event **AND**

iv. Member did not receive more than 9 cycles of Lenalidomide and had at least 9 months between the last dose of Lenalidomide and progression

OR

b. When used in combination with pomalidomide must have responded to previous treatment with proteosome inhibitor or lenalidomide, or both, but progressed within 6 months

AND

ii. The patient must have received 1 to 3 prior lines of therapies for the treatment of multiple myeloma.

AND

iii. Member must have documented progression following their most recent therapy.

Exclusion Criteria: Empliciti (elotuzumab) is not considered medically necessary when any of the following selection criteria is met:

1. Members with non-secretory or oligo-secretory or serum free light-chain only myeloma.
2. Members with active plasma cell leukemia.
3. Members with Known Human immunodeficiency virus (HIV) infection or active hepatitis A, B, or C.
4. Disease progression while taking Empliciti (elotuzumab).
5. The maximum dose should not exceed 10 mg/kg.
6. Indications not supported by CMS recognized compendia or acceptable peer reviewed literature may be deemed as not approvable and therefore not reimbursable.

IV. PROCEDURE

Requests for Empliciti (elotuzumab) shall be reviewed for appropriateness per FDA approved product labeling, the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) clinical guidelines, or CMS approved compendia.

1. **Dosage and Administration:**

a. Recommended Dosing when Used in Combination with Lenalidomide and Dexamethasone: 10 mg/kg administered intravenously every week for the first two cycles and every 2 weeks, thereafter, until disease progression or unacceptable toxicity. Administer in combination with lenalidomide 25 mg orally daily on days 1 through 21 and dexamethasone 28 mg orally (taken 3 to 24 hours prior to elotuzumab) on days 1, 8, 15, and 22 on cycles 1 and 2 and on days 1 and 15 of subsequent cycles; give dexamethasone 40 mg orally on days 8 and 22 of cycles 3 and beyond. Repeat treatment cycles every 28 days until disease progression.

b. Recommended Dosing when Used in Combination with Pomalidomide and Dexamethasone: 10 mg/kg IV once weekly on cycles 1 and 2 (on days 1, 8, 15, and 22), then give 20 mg/kg IV

every 4 weeks (on day 1) starting on cycle 3. Administer elotuzumab in combination with pomalidomide 4 mg orally daily on days 1 through 21 and oral dexamethasone (age 75 years or less, 28 mg; age over 75 years, 8 mg) at 3 to 24 hours prior to elotuzumab on days 1, 8, 15, and 22 on cycles 1 and 2 and on day 1 of subsequent cycles. Additionally, give oral dexamethasone (age 75 years or less, 40 mg; age over 75 years, 20 mg) at 3 to 24 hours prior to elotuzumab on days 8, 15, and 22 of cycles 3 and beyond. Repeat treatment cycles every 28 days until disease progression.

c. Premedicate with dexamethasone, diphenhydramine, ranitidine and acetaminophen.

2. D**osage Adjustments: Dosage adjustments are not required for renal or hepatic impairment.**

   a. Interrupt Empliciti (elotuzumab) for Grade 2 or higher infusion reactions and permanently discontinue for severe infusion reaction.

   b. Monitor liver function and stop if hepatotoxicity (grade 3 liver enzyme elevations or higher) is suspected.

3. **Monitoring**

   a. Monitor for fever and other signs of infection and treat promptly.

   b. Malignancy: Invasive second primary malignancies including solid tumors and skin cancer have been reported. Monitoring recommended.

V. APPROVAL AUTHORITY

1. Review – Utilization Management Department
2. Final Approval – Utilization Management Committee

VI. ATTACHMENTS

None

VII. REFERENCES

1. Empliciti prescribing information. Bristol-Myers Squibb 2018.
2. Clinical Pharmacology Elsevier Gold Standard. 2020.
3. Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, Co. 2020.
4. National Comprehensive Cancer Network. Cancer Guidelines and Drugs and Biologics Compendium. 2020.
5. AHFS Drug Information. American Society of Health-Systems Pharmacists or Wolters Kluwer Lexi-Drugs . Bethesda, MD. 2020.